European Commission Approves Revolution Medicines' RASONQUE (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Nov 16, 2026, 1:04 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
EC approval creates a legal pathway for commercial sales in the EU/EEA and therefore potential incremental revenue and cash flow for RVMD, although realized sales will depend on country-level pricing, health‑technology assessments and reimbursement timing.
AI summary
What happened, with direct paths to the underlying reporting
The European Commission granted marketing authorization for Revolution Medicines' RASONQUE (daraxonrasib) for previously treated metastatic pancreatic adenocarcinoma across the EU/EEA; approval is based on positive Phase 3 RASolute 302 results.
The European Commission has approved RASONQUE (daraxonrasib) for treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
RASONQUE is approved as once-daily oral tablets for adults with metastatic pancreatic adenocarcinoma with or without an identified RAS tumor mutation.
The EC granted marketing authorization covering all EU member states and EEA countries Iceland, Norway, and Liechtenstein.
The EC approval is based on the Phase 3 RASolute 302 trial, which met primary and key secondary endpoints in both the RAS G12 mutant population and the overall intent-to-treat population.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Revolution Medicines has started treating patients in global Phase 3 RASolve 308, evaluating zoldonrasib with pembrolizumab and platinum-based chemo for first-line G12D NSCLC. Apr…
An EMA committee recommended approval of Revolution Medicines' Rasonque in the EU for adults with metastatic pancreatic cancer after prior therapy, signaling a potential new reven…
FDA approves Revolution Medicines' targeted therapy for adults with metastatic pancreatic cancer who have prior treatment or cannot receive combination chemotherapy, expanding RVM…
Regulatory progress for Revolution Medicines' pancreatic cancer program emerged as the EMA initiated a rolling review of the company's experimental therapy. While not a guarantee…